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Abstract
Background: Histopathological grading of ependymoma has been controversial with respect to its reproducibility
and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from
European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/CNS9904) to assess
both diagnostic concordance among five neuropathologists and the prognostic utility of histopathological
variables, particularly tumor grading.
Results: In phase 1, using WHO criteria and without first discussing any issue related to grading ependymomas,
pathologists assessed and independently graded ependymomas from 3 of 4 trial cohorts. Diagnosis of grade II
ependymoma was less frequent than grade III, a difference that increased when one cohort (CNS9204) was
reassessed in phase 2, during which the pathologists discussed ependymoma grading, jointly reviewed all CNS9204
tumors, and defined a novel grading system based on the WHO classification. In phase 3, repeat independent
review of two cohorts (SFOP/CNS9904) using the novel system was associated with a substantial increase in
concordance on grading. Extent of tumor resection was significantly associated with progression-free survival (PFS)
in SFOP and AIEOP, but not in CNS9204 and CNS9904. Strength of consensus on grade was significantly associated
with PFS in only one trial cohort (AIEOP). Consensus on the scoring of individual histopathological features
(necrosis, angiogenesis, cell density, and mitotic activity) correlated with PFS in AIEOP, but in no other trial.
Conclusions: We conclude that concordance on grading ependymomas can be improved by using a more
prescribed scheme based on the WHO classification. Unfortunately, this appears to have utility in limited clinical
settings.
Background
Ependymoma is the third most common neuroepithelial
tumor of the central nervous system (CNS) in child-
hood, after astrocytoma and medulloblastoma [1,2]. It
currently presents a considerable therapeutic challenge,
being incurable in more than half of cases. In contrast
to the mainly spinal tumors of adults, childhood disease
is dominated by intracranial tumors [1]. Treatment of
pediatric intracranial ependymomas principally involves
surgery and adjuvant radiotherapy, extent of surgical
resection being a critical determinant of outcome [3].
The role of chemotherapy is controversial, but its use
alongside radiotherapy has been the focus of several
clinical trials, especially in the setting of attempts to
avoid or to defer radiotherapy in infants [4-6,3].
The World Health Organization (WHO) classification
of CNS tumors defines several histopathological variants
of ependymoma [1]. Aside from the subependymoma
(WHO grade I), which generally presents in adults and
causes minimal morbidity, and very rare examples of
intracranial myxopapillary ependymoma (WHO grade I),
intracranial pediatric ependymomas are divided between
classic (WHO grade II) and anaplastic (WHO grade III)
tumors. Whether children with one or other of these
two variants should be stratified onto different therapeu-
tic regimens remains contentious [5].
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dymomas appear heterogeneous; there is considerable
histopathological variation among tumors and within
tumors, with the result that grading them in any reliable
manner is difficult. Such difficulty is reflected by studies
of clinically similar cohorts of children with intracranial
ependymoma that report ratios of grade II to grade III
tumors that range between 17:1 and 1:7, a striking dis-
cordance that likely represents both intratumoral het-
erogeneity, the uneven application of criteria for
anaplasia by review pathologists, and idiosyncratic small
patient cohorts [7]. Whether children with grade II and
those with grade III ependymomas have significantly dif-
ferent outcomes also remains unclear; among articles
with a focus on prognostic factors, those that do not
show histopathological grade as an independent prog-
nostic or predictive factor outnumber those that do
[8-15,7].
Seeking to inform these difficult issues, we acquired
standard histopathological preparations of ependymomas
from children entered into four European clinical trials
for systematic review by five neuropathologists. The
review consisted of three phases: (1) grading tumors
according to each pathologist’s pre-study practice using
the WHO classification, (2) collective evaluation of
tumors from one trial cohort by all pathologists, with
discussion of difficulties associated with grading, and (3)
further independent review of cases following formula-
tion of a novel grading system based on histopathologi-
cal features from the WHO classification, but designed
to be more prescriptive.
Materials and methods
Trial cohorts
Ependymomas (n = 229) from children entered into four
European clinical trials were requested for histopatholo-
gical review, following Newcastle/North Tyneside
Research Ethics Committee approval for studies on
childhood brain tumors. An AIEOP trial with a postsur-
gical “stage-determined” protocol for non-infants pro-
vided 42 patients with a median age of 6.3 years [16].
Children on this trial were treated with (i) focal hyper-
fractionated radiotherapy (HFRT), if there was no evi-
dence of post-surgical residual disease, or (ii) 4 courses
of VEC followed by HFRT, if there was post-surgical
residual disease. The dose of HFRT was 70.4 Gy (1.1
Gy/fraction b.i.d.), and the VEC regimen consisted of
VCR 1.5 mg/m
2 1/w, VP16 100 mg/m
2/day x3, and
CTX 3 g/m
2/day x1. Where feasible, second-look sur-
gery was recommended. An SFOP trial aiming to treat
young (< 5 years) children with chemotherapy alone
provided 54 patients with a median age of 1.8 years [4].
Initial treatment was maximal surgical resection, which
was classified as complete when post-operative
neuroimaging was considered negative. Chemotherapy
consisted of cycles of three courses (A: carboplatin/pro-
carbazine, B: etoposide/cisplatin, C: vincristine/cyclopho-
sphamide) delivered each 21 days for 7 cycles.
Chemotherapy was discontinued if disease progression
or unacceptable toxicity occurred. No radiotherapy was
planned after completion of chemotherapy, but salvage
therapy (including second-look surgery and radiother-
apy) was only indicated for disease progression or a
relapse. Two CCLG (UKCCSG) SIOP trials - CNS9204
and CNS9904 - provided 84 and 49 patients respectively.
The CNS9204 protocol aimed to evaluate a primary che-
motherapy strategy for avoiding or delaying radiotherapy
in children aged less than 3 years with intracranial epen-
dymoma [6]. Maximal surgical resection was followed by
alternating blocks of myelo- and non-myelosuppressive
chemotherapy every 14 days for an intended duration of
1 year. Radiotherapy was withheld unless there was
recurrent disease. The overall strategy for CNS 9904
was similar to that of the AEIOP trial. After a complete
surgical resection of tumor, radiotherapy (54 Gy) was
delivered to the tumor site, but for those with an
incomplete resection chemotherapy with VEC preceded
radiotherapy (54 Gy). Across all trials, central review of
all operative reports was undertaken to establish extent
of surgical resection. Despite strenuous efforts, it was
not possible to acquire histological preparations from all
patients entered into each trial, success rates ranging
from 55% (CNS9904) through 67% (AIEOP) and 74%
(SFOP) to 95% (CNS9204). The clinical characteristics
of children whose tumors were reviewed on this study
are provided in Table 1 and are representative of those
for the entire trial cohorts. Figure 1 shows progression-
free survival (PFS) and overall survival (OS) for the trial
cohorts used in this study.
Pathology
Slides of sections stained with hematoxylin and eosin
(H&E) were used for pathological assessment. Ependy-
momas were graded according to each neuropatho-
logist’s independent interpretation of the WHO
classification of CNS tumors (phase 1) or (phase 3)
according to a novel grading scheme (Figure 2) that was
based on a prescribed application of the WHO classifi-
cation and devised by consensus following group review
of all tumors from patients on CNS9204 (phase 2). The
presence or absence of four histopathological features;
cell density, mitotic activity, microvascular proliferation
and necrosis, was recorded alongside application of the
novel grading scheme. Evaluation of ependymomas
according to the novel grading scheme recognized the
tendency of ependymomas to show three main patterns
of nuclear:cytoplasmic ratio; either low cell density, or
high cell density, or nodules of high cell density within
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mitotic activity, in which situation any mitotic figure
was difficult to detect across multiple high-powered
fields, was distinguished from the ability to detect (high)
mitotic activity by detecting at least five mitotic figures
while scanning just a few high-powered fields. Microvas-
cular proliferation was recorded as present when layers
of hyperplastic mural cells, rather than just hypertrophic
endothelial cells, were detected (Figure 3b).
Statistical analysis
Graphical tools and descriptive statistics were used to
describe the consensus among the five neuropatholo-
gists. Associations between clinical factors, as well as
strength of consensus on histopathological variables,
and progression-free survival (PFS) and overall survival
(OS), were investigated using multivariable Cox propor-
tional hazards models. P-values provided in the results
section are not adjusted for multiple testing.
Results
Phase 1: pre-consensus grading - CNS9204, CNS9904,
SFOP trials
Before any discussion of ependymoma grading, each
pathologist independently evaluated tumors from chil-
dren treated on the SFOP, CNS9204, and CNS9904
trials, allocating grade II or III. The proportions of epen-
dymomas allocated grade II and grade III ranged from
19% to 59% and 41% to 81% respectively across the
three trials. Figure 4 displays the ratios of grade II to
grade III tumors grouped by trial (a) and pathologist (b),
and Figure 5 displays agreement on grading by trial.
Phase 2: joint review of histopathological features/
grading - CNS9204 trial
Joint review of all ependymomas from the CNS9204 trial
cohort led to a consensus of 25 (30%) grade II and 59
(70%) grade III tumors. In achieving consensus on the
grading of ependymomas from this cohort, some pathol-
ogists accepted a greater shift away from their usual
practice than others (Figure 6). Following the joint
review, discussion of (i) idiosyncratic cases encountered
in clinical practice, and (ii) problems with evaluating
types of necrosis in both grade II and grade III tumors
produced further refinement of our views on grading
and led to the creation of a novel grading scheme (Fig-
ure 2). This scheme emphasizes regions of high cell
density, mitotic activity, and angiogenesis for grading
purposes, while dismissing the influence of necrosis and
cytological atypia.
Phase 3: post-consensus grading - AIEOP trial
Ependymomas from children entered on the AIEOP trial
were available for review in phase 3 of the study only.
Grade II and III ependymomas represented 31%-43%
and 57%-69% of tumors depending on pathologist;
results that match those for CNS9904, with its similar
patient population (Figure 7a).
Phase 3: post-consensus repeat grading - CNS9904, SFOP
trials
A second independent evaluation of ependymomas from
CNS9904 and SFOP based on the new classification
allowed us to assess concordance on grading among
pathologists before and after consensus was reached on
the creation of a novel grading scheme. In both trial
cohorts, there was a substantial improvement in agree-
ment on grades (Figures 5, 7b, and 7c); cases for which
there was perfect agreement increased from 33% to 67% in
CNS9904 (p = 0.0001) and from 42% to 55% in SFOP (p =
0.006). Cases for which there was perfect agreement or
only one dissenter increased from 73% to 86% in
CNS9904 (p = 0.065) and 69% to 78% in SFOP (p = 0.013).
Post-consensus concordance on histopathological
variables
Cell density, mitotic activity, angiogenesis, and necrosis
were histopathological variables assessed as part of the
phase 3 review of ependymomas from children on the
CNS9904, SFOP, and AIEOP trials. Strength of consensus
Table 1
SFOP CNS9204 AIEOP CNS9904 ALL PATIENTS
Age at Diagnosis Median 1.8 1.9 6.3 6.8 .
IQR 1.3-2.5 1.4-2.4 4.3-11.3 5.0-11.5 .
Sex Female 28 (52%) 30 (36%) 18 (43%) 23 (47%) 99 (43%)
Male 26 (48%) 54 (64%) 24 (57%) 26 (53%) 130 (57%)
Tumor Site Unknown .8.. 8
Infratentorial 45 (83%) 69 (91%) 31 (74%) 36 (74%) 181 (82%)
Supratentorial 9 (17%) 7 (9%) 11 (26%) 13 (26%) 40 (18%)
Surgical excision Complete 35 (65%) 43 (51%) 29 (69%) 19 (39%) 126 (55%)
Incomplete 19 (35%) 41 (49%) 13 (31%) 30 (61%) 103 (45%)
ALL PATIENTS 54 84 42 49 229
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angiogenesis than other variables (Figures 8a-d).
Association between outcome and clinical variables
For each trial, outcome analyses were undertaken using
clinical and pathological data. The following clinical
variables were considered: age at diagnosis, gender,
tumor site, and surgery extent. PFS and OS were signifi-
cantly associated with extent of surgical resection in the
AIEOP (PFS: p = 0.003; OS: p = 0.014) and SFOP (PFS:
p = 0.003; OS: p = 0.016) cohorts. In the SFOP cohort,
OS was also significantly associated with tumor site;
infratentorial tumors were associated with a worse out-
come (p = 0.025). In CNS9204, age at diagnosis was
associated with OS, young age being correlated with a
worse outcome (p = 0.012). No other clinical variable




Figure 1 Progression-free (PFS) and overall survival (OS) in four European trials.( a)P F Sa n d( b) OS by trial. Black line = SFOP; red line =
CNS9204; blue line = CNS9904; and green line = AIEOP.
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grading
Data from phase 1 of the study, when ependymomas
from trial cohorts CNS9204, SFOP, and CNS9904 were
graded independently by each of the pathologists
according to their usual diagnostic practice, revealed no
association between strength of consensus on grade and
outcome.
In phase 2 of the study using trial cohort CNS9204,
when tumor grade and the status of 4 histopathological
features were agreed by all 5 pathologists around a
multi-headed microscope, no pathological variable was
shown to be prognostic indicator.
When ependymomas from CNS9904, SFOP and
AIEOP were evaluated independently by each patholo-
gist in phase 3 of the study, there was no association
between strength of consensus among pathologists on
grade and PFS for children treated on CNS9904 and
SFOP. Similarly, there was no association between PFS
for children treated on CNS9904 and SFOP and the
strength of consensus among pathologists on the status
of any individual histopathological feature. In contrast,
strength of consensus among pathologists on grade and
on every histopathological variable was significantly
correlated with PFS in the AIEOP trial cohort. Combi-
nations of consensus grade and extent of surgical
resection produced significantly different survival
curves (PFS and OS) when examined in the AIEOP
cohort only (Figure 9).
The above results were unchanged, if instead of degree
of consensus, the calls of individual pathologists on
grade and histopathological variables were analyzed
against outcome. Overall, no one pathologist’sa p p r o a c h
to the assessment of ependymomas prevailed as a corre-
late of biological behavior.
Discussion
No previous international study has systematically
addressed the histopathological evaluation of ependymo-
mas in the manner reported here, providing data on the
review of 229 intracranial ependymomas from children
entered into 4 European trials. The review was con-
ducted by 5 neuropathologists, all with specialist experi-
ence in the field of pediatric neuro-oncology. The final
phase of the study (phase 3) employed a novel histo-
pathological grading scheme. This represents a pre-
scribed application of the WHO classification and was
derived by consensus from both the pathologists’ experi-
ence of ependymomas and a joint review of tumors
from one of the four trials (CNS9204). Key aims of the
study were: (i) to assess whether discussion surrounding
the conception of the new grading scheme and its prin-
ciples could be used to improve concordance on grading
among pathologists, and (ii) whether any pathological
variable, either grade itself or the status of one of four
histopathological features, was associated with outcome
in the setting of formal ependymoma clinical trials with
different therapeutic approaches.
Figure 2 Novel grading scheme for pediatric intracranial classic (grade II) and anaplastic (grade III) ependymomas, in which “nodules”
are regions of high cell density.
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to grade childhood intracranial ependymomas; a huge
discrepancy exists between the ratio of grade II:III
tumors across the literature, and there is considerable
scepticism as to whether grading intracranial ependymo-
mas has clinical utility [7]. The 2007 WHO classification
distinguishes the anaplastic (grade III) from classic
(grade II) ependymoma on the basis of “high mitotic
activity, often accompanied by microvascular prolifera-
tion and pseudopalisading necrosis” [1]. This reflects a
general principle of the pathological assessment of glio-
mas - that the identification of ‘anaplastic’ features, such
as increased cell density, mitotic activity, microvascular
proliferation, and necrosis, can be used to derive a clini-
cally useful grade. In diffuse astrocytic tumors, these
features are progressively acquired with increasing grade
(fibrillary astrocytoma, grade II - anaplastic astrocytoma,
grade III - glioblastoma, grade IV) and are recognized
prognostic indicators [17,1]. Reinforcing the biological
relevance of histopathological grading, astrocytoma pro-
gression is associated with the acquisition of specific
genetic abnormalities [1]. In contrast, anaplastic ependy-
momas tend to present de novo; it is uncommon for
recurrent ependymomas progressively to acquire an ana-
plastic phenotype, and any genetic basis for this phe-
nomenon has not yet been convincingly demonstrated
[18]. In addition, the presence of anaplastic features
across an ependymoma is notoriously variable in magni-
tude and extent, potentially making evaluation of these
features difficult and subsequent grading subjective. For
example, a pathologist may be faced with a small focus
of microvascular proliferation or pseudopalisading
necrosis in a tumor devoid of mitotic activity and with a
low cell density. Should this discovery prompt a diagno-
sis of anaplastic ependymoma (grade III), or should the
dominant grade II phenotype prevail?
In phase 1 of this study and before discussing the
grading of ependymomas, the five study neuropatholo-
gists showed only fair concordance for grade among the
group, while showing individual consistency across
trials. If ependymomas are particularly difficult tumors
to grade, it is surprising that the levels of inter-observer
concordance recorded in this study are not far removed
from those reported for other gliomas. Assessing astro-
cytomas and oligodendrogliomas, Coons and colleagues
reported an initial 4-reviewer concordance on grade of
52%, which compares with 51% for 5/5 consensus on
grading in CNS9204 in this study [19]. Mirroring our
experience, concordance improved over successive
reviews, as their pathologists discussed possible explana-
tions for discrepancies and developed criteria to aid
grading. Grade was assigned according to the status of
the same histopathological variables used in the present
study, among which microvascular proliferation proved
hardest to evaluate in both studies, with lower levels of
agreement on its status than for other histopathological
features.
After discussing the problems of grading ependymo-
mas and devising a novel grading scheme (phase 2), our
study pathologists assessed ependymomas from two trial
cohorts for a second time at an interval of just over one
year (phase 3). Concordance on grading was notably
improved at this time, though it was apparent that some
pathologists altered their practice to accommodate the
new scheme more than others. This outcome does not
necessarily suggest that the new grading scheme pre-
sented here is better than the WHO classification, to
which the neuropathologists were working in phase 1 of




Figure 3 Specific histopathological characteristics of
ependymoma. (a) A nodule of moderately high cell density against
a low cell density background. (H&E, × 40). (b) The tumor
vasculature here shows mural cell hyperplasia and qualifies as
microvascular proliferation (H&E, ×100).
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Figure 4 Grading of ependymomas in three European trials by five neuropathologists (phase 1 of study).( a) Proportions of tumors
classified as grade II (dark gray) or grade III (light gray) by neuropathologists A-E in phase 1 of the study, grouped by trial. (b) Proportions of
tumors classified by each neuropathologist (Path-A, Path-B etc.) in phase 1 of the study as grade II (dark gray) or grade III (light gray).
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Page 7 of 13Figure 5 Proportions of tumors in the three trial cohorts for which there was 4/5 or 5/5 agreement on grade among five pathologists
during phase 1 of the study.
Figure 6 Percentages of tumors from the CNS9204 cohort for which each neuropathologist’s independent grade assignment (phase 1)
matched the consensus grade after joint review by all pathologists (phase 2); e.g. pathologist A independently classified 22/84 tumors as
grade II and 62/84 tumors as grade III during phase 1, while in phase 2, joint review classified 17/22 and 54/62 as grade II and grade III tumors,
respectively, producing an overall “match” on 71/84 tumors.
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Figure 7 Grading of ependymomas in three European trials by five neuropathologists (phase 3 of study). (a) Proportions of tumors
classified as grade II (dark gray) or grade III (light gray) among trial cohorts. (b) Proportions of tumors classified as grade II (dark gray) or grade
III (light gray) in two trial cohorts (SFOP & CNS9904) before (phase 1; pre-TR) or after (phase 3; post-TR) review of CNS9204 cohort in phase 2 of
study (TR). (c) Proportions of tumors in three trial cohorts for which at least 4 of the 5 neuropathologists agreed on grade.
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However, one corollary of the improvement could be
that it is easier to grade ependymomas consistently
using a more detailed and prescribed scheme than the
current WHO classification.
Various clinical variables have been associated with
outcome in trial cohorts of children with intracranial
ependymoma. These include age at presentation, tumor
location, and extent of surgical resection [9,4,15,20-24].
In addition, there is undoubted evidence to indicate the
benefits of radiotherapy [5,3,14]. A trend towards
shorter PFS and OS in the infant cohorts (SFOP/
CNS9204) was observed, but in the present study a sig-
nificant positive association between age and OS (but
not PFS) was observed only among children from the
CNS9204 cohort. Infratentorial tumor location was sig-
nificantly associated with poorer OS (but not PFS) only
among children from the SFOP cohort. Extent of surgi-
cal resection, which has been a proven prognostic indi-
cator in most studies of pediatric ependymoma [22,23],
was associated with outcome in only two (SFOP/
AIEOP) out of four of the present trial cohorts, and it
may be relevant that the proportion of completely
excised tumors in these trial cohorts (SFOP = 65%;
AIEOP = 69%) is greater than in either the CNS9204
(51%) or CNS9904 (39%) trial.
The study design enabled us to examine potential
associations between outcome and multiple histopatho-
logical features. With assessments from five pathologists,
it was also possible to analyze the relationship between
outcome and strength of consensus among pathologists
on grade or the status of individual histopathological
features. Adjusted for extent of surgical resection,
strength of consensus on grade and on each of the his-
topathological features was significantly associated with
PFS in the AIEOP cohort, but in none of the other
cohorts. When individual pathologists’ calls on these
variables were reviewed; grade III, high cell density, high
mitotic activity, presence of microvascular proliferation,
and presence of necrosis were all significant adverse
prognostic indicators for the AIEOP cohort, but not for
SFOP or CNS9904. In the setting of satisfactory concor-
dance on histopathological interpretation, our results
suggest that grading ependymomas might have clinical
utility either in older children (versus infants) or in chil-
dren that have received radiotherapy immediately post-
surgery (usually non-infants). The latter conclusion is




Figure 8 Strength of consensus among neuropathologists on histological variables. Consensus on (a) cell density, (b) mitotic activity, (c)
microvascular proliferation, and (d) necrosis was closely matched across studies during phase 3, but was lower for angiogenesis than for other
variables.
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all ages, including infants, that were treated with radio-
therapy soon after surgery [25]. However, a major caveat
from our study involves the lack of a similar association
in children from the CNS9904 cohort. These discrepant
findings might be related to different proportions of com-
pletely versus incompletely resected tumors in the AIEOP
(69% vs. 31%) and CNS9904 (39% vs. 61%) cohorts.
There are few fundamental differences between studied
cohorts to explain our data; there was a significant asso-
ciation between extent of surgical resection and outcome
in the AIEOP and SFOP but not the CNS9204 and
CNS9904 series, and irradiation as a first line treatment
was incorporated into the AIEOP, but not SFOP, trial.
Our data also suggest that a more robust assessment
of ependymomas for therapeutic purposes may await the


Figure 9 Progression-free (PFS) and overall survival (OS) in AIEOP trial cohort patients split according to histological grade and extent
of surgical resection, showing significantly different survival curves (PFS p = 0.0004; OS p < 0.0001). (a) PFS and (b) OS. CR = complete
resection; STR = subtotal resection; black line = CR-Gd. II; red line = STR-Gd. II; blue line = CR-Gd. III; green line = STR-Gd. III
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tological and molecular approaches, but while markers
of tumor cell proliferation, e.g. Ki-67 immunolabeling
[9,26-28], and a few molecular abnormalities, e.g. copy
number gain across chromosome 1q and ERBB2/4
receptor expression [29-32], have been proposed as
prognostic indicators, insufficiently unambiguous data
are available from large patient cohorts for the confident
creation of such a scheme. It is also possible that conti-
nuing difficulties with finding prognostic markers for
this tumor reflect a misplaced view of ependymomas as
homogeneous across the neuraxis, a principle implicit in
the WHO classification, which does not differentiate
between supratentorial and posterior fossa tumors.
However, both data showing that ependymomas at these
two sites are characterized by distinct gene expression
profiles and identification of a ‘vascular’ variant in a
mainly supratentorial location make the case that epen-
dymomas from these sites should probably be appraised
separately [33,34].
Conclusions
We have provided a substantial amount of data on the
histopathological evaluation of pediatric intracranial
ependymoma and its clinical associations. Being more
prescribed than the latest WHO classification in its
approach to grading ependymomas, the novel scheme we
describe may offer advantages with respect to reproduci-
bility and its ability to link the pathology of ependymo-
mas to outcome, and we would welcome more studies of
its effectiveness in other ependymoma trial cohorts.
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